4DMT’s 4D-150 gene drug for the intravitreal treatment of wet AMD received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, the first RMAT designation for wet AMD

4DMT’s 4D-150 gene drug for the intravitreal treatment of wet AMD received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, the first RMAT designation for wet AMD

4D Molecular Therapeutics Inc. The designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related …

Read more

Researchers show how to actively change magnetism through pressure

Researchers show how to actively change magnetism through pressure

In situ strain tuning of frustrated magnetism in Y3copper9(oh)19chlorine8. (a)(c) For NMR experiments under uniaxial strain, a single crystal is bonded between two arms of a piezoelectric strain unit (a), …

Read more

2024 warning: The losers of the green revolution will not go quietly

2024 warning: The losers of the green revolution will not go quietly

Press play to listen to this article Voiced by artificial intelligence. After spearheading the Green Revolution, Europe now lives in its shadow: the counterrevolution. I spent much of the last …

Read more

Supercomputer delivers new Lyman Forest simulation suite to illustrate large-scale structure of universe

Supercomputer delivers new Lyman Forest simulation suite to illustrate large-scale structure of universe

TACC’s Frontera supercomputer helped astronomers develop PRIYA, the largest suite of fluid dynamics simulations of large structures in the universe to date. Example Lyman forest spectrum of quasar light and …

Read more

Myriad Genetics Chief Financial Officer Bryan Riggsbee retires; Scott Leffler named successor; reiterates previously issued financial guidance

Myriad Genetics Chief Financial Officer Bryan Riggsbee retires; Scott Leffler named successor; reiterates previously issued financial guidance

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as …

Read more